Yuen N, Lemaire M, Wilson S
PLoS Genet. 2024; 20(12):e1011484.
PMID: 39652523
PMC: 11627368.
DOI: 10.1371/journal.pgen.1011484.
Koukou Z, Panteris E, Manolakos E, Papadopoulos A, Papoulidis I, Relakis K
Biomed Rep. 2024; 20(4):69.
PMID: 38495346
PMC: 10941718.
DOI: 10.3892/br.2024.1757.
Gajic M, Schroder-Heurich B, Mayer-Pickel K
Front Pharmacol. 2024; 15:1298928.
PMID: 38375029
PMC: 10875033.
DOI: 10.3389/fphar.2024.1298928.
Xing L, Bai T, Liu S, Liu J, Jing X, Deng C
Front Pediatr. 2023; 11:1195818.
PMID: 37664552
PMC: 10469925.
DOI: 10.3389/fped.2023.1195818.
Hong J, Kumar S
Clin Sci (Lond). 2023; 137(8):579-595.
PMID: 37075762
PMC: 10116344.
DOI: 10.1042/CS20220300.
Soluble suppression of tumorigenicity-2 in pregnancy with a small-for-gestational-age fetus and with preeclampsia.
Kanninen T, Jung E, Gallo D, Diaz-Primera R, Romero R, Gotsch F
J Matern Fetal Neonatal Med. 2022; 36(1):2153034.
PMID: 36521862
PMC: 10291739.
DOI: 10.1080/14767058.2022.2153034.
Hypertensive disorders of pregnancy share common cfDNA methylation profiles.
Spinelli M, Zdanowicz J, Keller I, Nicholson P, Raio L, Amylidi-Mohr S
Sci Rep. 2022; 12(1):19837.
PMID: 36400896
PMC: 9674847.
DOI: 10.1038/s41598-022-24348-6.
The role of miRNA-210 in pre-eclampsia development.
Jaszczuk I, Koczkodaj D, Kondracka A, Kwasniewska A, Winkler I, Filip A
Ann Med. 2022; 54(1):1350-1356.
PMID: 35543206
PMC: 9103497.
DOI: 10.1080/07853890.2022.2071459.
Circulating Total Cell-Free DNA Levels Are Increased in Hypertensive Disorders of Pregnancy and Associated with Prohypertensive Factors and Adverse Clinical Outcomes.
Amaral L, Sandrim V, Kutcher M, Spradley F, Cavalli R, Tanus-Santos J
Int J Mol Sci. 2021; 22(2).
PMID: 33429954
PMC: 7826953.
DOI: 10.3390/ijms22020564.
Maternal total cell-free DNA in preeclampsia with and without intrauterine growth restriction.
Kwak D, Kim S, Kim H, Lim J, Kim Y, Ryu H
Sci Rep. 2020; 10(1):11848.
PMID: 32678284
PMC: 7367308.
DOI: 10.1038/s41598-020-68842-1.
Usefulness and reliability of cell free fetal DNA screening for main trisomies in case of atypical profile on first trimester maternal serum screening.
Carrara J, Vivanti A, Jani J, Demain A, Costa J, Benachi A
J Transl Med. 2019; 17(1):398.
PMID: 31779618
PMC: 6883576.
DOI: 10.1186/s12967-019-02152-7.
Maternal total cell-free DNA in preeclampsia and fetal growth restriction: Evidence of differences in maternal response to abnormal implantation.
Rafaeli-Yehudai T, Imterat M, Douvdevani A, Tirosh D, Benshalom-Tirosh N, Mastrolia S
PLoS One. 2018; 13(7):e0200360.
PMID: 30001403
PMC: 6042756.
DOI: 10.1371/journal.pone.0200360.
Circulating cell-free DNA concentration and DNase I activity of peripheral blood plasma change in case of pregnancy with intrauterine growth restriction compared to normal pregnancy.
Ershova E, Sergeeva V, Klimenko M, Avetisova K, Klimenko P, Kostyuk E
Biomed Rep. 2017; 7(4):319-324.
PMID: 29085628
PMC: 5649650.
DOI: 10.3892/br.2017.968.
Do miRNAs Play a Role in Fetal Growth Restriction? A Fresh Look to a Busy Corner.
Chiofalo B, Lagana A, Vaiarelli A, La Rosa V, Rossetti D, Palmara V
Biomed Res Int. 2017; 2017:6073167.
PMID: 28466013
PMC: 5390605.
DOI: 10.1155/2017/6073167.
Cell-Free Fetal DNA for the Prediction of Pre-Eclampsia at the First and Second Trimesters: A Systematic Review and Meta-Analysis.
Contro E, Bernabini D, Farina A
Mol Diagn Ther. 2016; 21(2):125-135.
PMID: 27838884
DOI: 10.1007/s40291-016-0245-9.
Cell-Free Total and Fetal DNA in First Trimester Maternal Serum and Subsequent Development of Preeclampsia.
Silver R, Myatt L, Hauth J, Leveno K, Peaceman A, Ramin S
Am J Perinatol. 2016; 34(2):191-198.
PMID: 27398706
PMC: 5358543.
DOI: 10.1055/s-0035-1570383.
Circulating Maternal Total Cell-Free DNA, Cell-Free Fetal DNA and Soluble Endoglin Levels in Preeclampsia: Predictors of Adverse Fetal Outcome? A Cohort Study.
AbdelHalim R, Ramadan D, Zeyada R, Nasr A, Mandour I
Mol Diagn Ther. 2016; 20(2):135-49.
PMID: 26790664
DOI: 10.1007/s40291-015-0184-x.
Cell-free fetal DNA and pregnancy-related complications (review).
Sifakis S, Koukou Z, Spandidos D
Mol Med Rep. 2014; 11(4):2367-72.
PMID: 25530428
PMC: 4337476.
DOI: 10.3892/mmr.2014.3118.
First trimester screening of circulating C19MC microRNAs can predict subsequent onset of gestational hypertension.
Hromadnikova I, Kotlabova K, Hympanova L, Doucha J, Krofta L
PLoS One. 2014; 9(12):e113735.
PMID: 25502889
PMC: 4266496.
DOI: 10.1371/journal.pone.0113735.
Circulating C19MC microRNAs in preeclampsia, gestational hypertension, and fetal growth restriction.
Hromadnikova I, Kotlabova K, Ondrackova M, Kestlerova A, Novotna V, Hympanova L
Mediators Inflamm. 2013; 2013:186041.
PMID: 24347821
PMC: 3848305.
DOI: 10.1155/2013/186041.